01 Shift Toward Comprehensive Genomic Testing for Complex and Rare Diseases The human genetics market is shifting from narrowly targeted genetic tests toward broader genomic approaches, particularly whole-exome and whole-genome sequencing. These methods can examine substantially larger portions of an individual’s DNA when conventional testing does not identify a disease-causing variant, increasing the role of comprehensive sequencing in clinical diagnosis and rare-disease evaluation. In July 2026, the FDA continued to maintain regulatory classifications for next-generation sequencing-based testing, reflecting the expanding use of high-throughput sequencing technologies in genetic analysis.
02 Growing Integration of Genetic Testing Into Precision Healthcare The market is increasingly moving toward using genetic information alongside clinical characteristics to guide disease diagnosis, treatment selection, and risk assessment. This is strengthening the role of genomic testing within precision medicine, where genetic variants can help clinicians identify appropriate therapies and improve treatment decisions for genetically influenced diseases and cancers. In August 2026, the FDA maintained updated information on nucleic-acid-based tests covering human genetic tests used to analyze DNA or RNA variations for disease diagnosis and genetic carrier status.
01 Increasing Use of Genetic Testing for Rare and Undiagnosed Conditions The increasing need to identify genetic causes of complex and rare diseases is driving demand for human genetics services and sequencing technologies. Healthcare providers can use exome or whole-genome sequencing when conventional testing fails to establish a diagnosis, creating demand for advanced sequencing, variant interpretation, and genetic analysis services.
01 Uncertain Clinical Interpretation of Genetic Variants Limits Broader Adoption The large volume of variants identified through comprehensive sequencing can restrict clinical adoption because many detected genetic changes have uncertain relationships with disease. This creates additional requirements for expert interpretation, clinical validation, and genetic counseling, increasing the complexity of using genomic results in routine care.
01 Expansion of Genomic Data Platforms Creates Opportunities for Variant Interpretation Services The growing volume of genomic information is creating opportunities for companies that provide bioinformatics, variant databases, interpretation software, and data-sharing infrastructure. Solutions that connect sequencing results with validated genetic databases can help laboratories and clinicians translate complex genomic data into clinically useful information.
01 Maintaining Analytical Accuracy Across Expanding Sequencing Workflows The expansion of sequencing-based testing creates challenges in maintaining consistent analytical performance across laboratories, platforms, bioinformatics pipelines, and test types. Differences in sequencing methods and interpretation approaches can affect the reliability and clinical usefulness of results, increasing the need for standardized validation and quality controls.
June 2026 Tempus AI acquired Deep 6 AI, expanding its AI-powered clinical trial matching and precision medicine capabilities to strengthen genomic research and human genetics applications.
March 2026 Illumina launched the MiSeq i100 Series sequencing systems in additional global markets, expanding access to next-generation sequencing for clinical genetics and human genomics research.
September 2025 QIAGEN completed the acquisition of Genoox, integrating AI-powered genomic interpretation with its molecular testing portfolio to enhance clinical genetics and precision medicine workflows.
May 2025 PacBio partnered with the University of Washington to expand the use of HiFi long-read sequencing for large-scale human genetics research, supporting improved identification of complex genetic variants.